Baxter International
BAX · NYSE · Healthcare · United States
Financials at a glance
Source: SEC XBRLAnnual
Quarterly · last 8
Revenue (FY2025)
$11.2B
Net margin
-8.5%
ROE
-15.6%
Revenue CAGR (2y)
+4.2%
EPS (FY2025)
-1.87
Net profit (FY2025)
$-957.0M
Ask MarketChacha about BAX
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Why it moved
- Jul 28, 2026
Baxter shares rose 4.41% after TD Cowen raised its price target to $24 from $20 (Hold) and Stifel raised its target to $24 from $19 (Hold) on July 28.
- Jul 27, 2026
BAX rose after TD Cowen raised its price target to $24 from $20 (maintaining Hold) on July 27.
source 1 ↗· confidence: high - Jul 24, 2026
No specific company catalyst or filing was reported today; the stock rose with broader market or sector movement ahead of its Q2 earnings release scheduled for July 30.
· confidence: low
Daily moves with the verified reason behind them. Education only — not investment advice.
Financials
Yearly
| Period | Revenue | Net profit | EPS | Net margin | ROE |
|---|---|---|---|---|---|
| FY2025 | $11.2B | $-957.0M | -1.87 | -8.5% | -15.6% |
| FY2024 | $10.6B | $-649.0M | -1.27 | -6.1% | -9.3% |
| FY2023 | $10.4B | $2.7B | 5.23 | 25.6% | 31.6% |
Quarterly
| Period | Revenue | Net profit | EPS | Net margin |
|---|---|---|---|---|
| 2026Q2 | $3.0B | $126.0M | 0.24 | 4.3% |
| 2026Q1 | $2.7B | $-15.0M | -0.03 | -0.6% |
| 2025Q3 | $2.8B | $-46.0M | -0.09 | -1.6% |
| 2025Q2 | $2.8B | $91.0M | 0.18 | 3.2% |
| 2025Q1 | $2.6B | $126.0M | 0.25 | 4.8% |
| 2024Q4 | $2.8B | $-512.0M | -1.00 | -18.6% |
| 2024Q3 | $2.7B | $140.0M | 0.27 | 5.2% |
| 2024Q2 | $2.7B | $-314.0M | -0.61 | -11.7% |
| 2024Q1 | $2.5B | $37.0M | 0.07 | 1.5% |
| 2023Q4 | $2.7B | $245.0M | 0.48 | 9.0% |
| 2023Q3 | $2.6B | $2.5B* | 4.93 | — |
| 2023Q2 | $2.6B | $-141.0M | -0.28 | -5.4% |
| 2023Q1 | $2.4B | $44.0M | 0.09 | 1.8% |
* Net profit includes one-off / non-operating items (e.g. a settlement or accounting gain), so it doesn’t reflect operating performance — net margin is hidden for that period.
Figures as reported, in reporting currency. Source: SEC XBRL.
Filings & announcements
2026
- SEC8/4/2026material
- SEC8/4/2026material
- SEC7/30/2026
- SEC7/30/2026material
- SEC7/14/2026material
- SEC4/30/2026material
- SEC4/30/2026
- SEC3/19/2026material
- SEC3/16/2026material
- SEC2/12/2026material
- SEC2/12/2026
2025
- SEC12/22/2025material
- SEC11/25/2025material
- SEC11/19/2025material
- SEC11/19/2025material
- SEC11/12/2025material
- SEC11/4/2025
- SEC10/30/2025material
- SEC10/21/2025material
- SEC8/5/2025
- SEC7/31/2025material
In the news
- Baxter International stock extends Q2 rally as guidance and peers highlight momentumAD HOC NEWS · 8/17/2026
- Baxter International (BAX) On Earnings Beat And Higher Guidance Has Fair Value Back In Focussimplywall.st · 8/13/2026
- Baxter International stock edges lower as market digests recent rating and price recoveryAD HOC NEWS · 8/13/2026
- Bank of America Securities Sticks to Its Hold Rating for Baxter International (BAX)The Globe and Mail · 8/12/2026
- Why Baxter (BAX) Is Up 5.3% After $500 Million Debt Tender And CFO Transition Newssimplywall.st · 8/9/2026
- Baxter (BAX) Stock May Be 25% Undervalued As Q2 Outlook Improvessimplywall.st · 8/6/2026
- Baxter International Sees Unusually Large Options Volume (NYSE:BAX)MarketBeat · 8/3/2026
- Do Wall Street Analysts Like Baxter International Stock?webull.com · 8/1/2026
Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.